Overview

A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours

Status:
Completed

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

The study is a first in man, dose escalation study to evaluate the safety, tolerability and how the drug works in the body in patients with all solid tumours. The aim of this study is to determine the most effective dose of the study drug that can then be further investigated in patients with advanced melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

Royal Marsden NHS Foundation Trust

Collaborators:

Biomedical Research Centre for Cancer
Institute of Cancer Research, United Kingdom
Wellcome Trust